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ABSTRACT  In the process of clinical diagnosis and treatment, the restricted mean 
survival time (RMST), which reflects the life expectancy of patients up to a specified time, 
can be used as an appropriate outcome measure. However, the RMST only calculates the 
mean survival time of patients within a period of time after the start of follow-up and may 
not accurately portray the change in a patient’s life expectancy over time. The life 
expectancy can be adjusted for the time the patient has already survived and defined as the 
conditional restricted mean survival time (cRMST). A dynamic RMST model based on the 
cRMST can be established by incorporating time-dependent covariates and covariates with 
time-varying effects. We analysed data from a study of primary biliary cirrhosis (PBC) to 
illustrate the use of the dynamic RMST model. The predictive performance was evaluated 
using the C-index and the prediction error. The proposed dynamic RMST model, which can 
explore the dynamic effects of prognostic factors on survival time, has better predictive 
performance than the RMST model. Three PBC patient examples were used to illustrate 
how the predicted cRMST changed at different prediction times during follow-up. The use 
of the dynamic RMST model based on the cRMST allows for optimization of 
evidence-based decision-making by updating personalized dynamic life expectancy for 
patients. 
Keywords: survival analysis; time-dependent covariates; conditional restricted mean 
survival time; dynamic prediction; nonproportional hazards 
  




Time-to-event outcomes, such as overall survival or progression-free survival, are often 
used as the primary endpoint for clinical trials in many diseases. In this context, survival 
curves are estimated by the Kaplan-Meier method, and comparisons are performed by the 
log-rank test. The hazard ratio (HR) obtained from the Cox proportional hazards (PHs) 
regression model is used to quantify treatment effects. However, the Cox model must 
satisfy the PHs assumption that the HR is constant over time, which often fails during 
long-term follow-up1,2. Furthermore, as the ratio of hazard rates (or hazard functions) in the 
two groups, the HR is difficult to interpret and hard to translate into clinical benefits in 
terms of a prolonged survival time3-5. As an alternative, the restricted mean survival time 
(RMST) is a good summary of the survival distribution, and the treatment effect can be 
quantified by the difference in the RMST between two treatment groups6-8. 
Generally, after being diagnosed (such as at the time of diagnosis or after a period of 
treatment), one of the key questions that is often asked by patients is "How long will I 
live?". This question can be answered by estimating the mean survival time. For example, 
Fig. 1 shows the survival curve of patients with primary biliary cirrhosis (PBC) from a 
clinical trial9, and the area under the entire curve is their mean survival time. However, the 
mean survival time cannot be estimated unless follow-up is continued until each subject has 
experienced the event of interest (or in the presence of censoring, until the survival curve 
has reached zero)3. In Fig. 1, the follow-up time of this trial was actually 14.31 years, and it 
was impossible to observe survival after the end of follow-up. At this time, the area under 
the survival curve up to 14.31 years can be calculated, that is, the 14.31-year RMST. It is 
readily interpretable as the mean survival time or "life expectancy" between the start of 
follow-up and a specific time point ( 14.31)τ τ = 7,10,11. 
It is worth noting that patients may want to know their prognosis at any time during 
follow-up, which requires the continuous prediction of life expectancy at a different 
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prediction times, represented by s. As shown in Fig. 2, a PBC patient started follow-up at 
0s s=  and underwent liver transplantation at 1s s= . The question "How long will I live?" 
is equally pressing at 1s s=  as it was at the start of follow-up ( 0s s= ). However, the 
patient’s life expectancy may vary at different prediction times. First, in the time between 
0s  and 1s , important events have taken place, such as surgical treatment, that may alter a 
patient’s life expectancy. Second, some variables that have an impact on the outcome may 
exhibit time-varying effects, resulting in a change in life expectancy as time progresses12-14. 
For instance, due to the possibility of postoperative infection and/or transplant rejection, the 
life expectancy of this patient will be reduced at 1s s=  but then greatly improved at 
2s s=  if the early postoperative period can be successfully survived. Third, some clinical, 
biochemical and histological indicators (e.g., coagulation indicators) are often measured in 
subjects at each follow-up visit; these response data give rise to time-dependent covariates 
(or longitudinal data). Changes in these indicators will also have an impact on life 
expectancy. 
In view of this, the continually updating life expectancy or mean survival time 
depending on the prediction time s is defined as the conditional restricted mean survival 










=  , 
where ( )S t  denotes the survival function, s is the prediction time (more precisely, the time 
of the prediction) and w is the time window. For example, m(0,5) represents the life 
expectancy of the patient in the next 5 years from the start of follow-up, which is equivalent 
to the 5-year RMST, while m(3,5) means the life expectancy in the next 5 years of a patient 
who had already survived for 3 years from the start of follow-up. The difference in 
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cRMSTs between groups is represented by md(s,w). This concept of obtaining/updating the 
life expectancy at different prediction times by considering time-dependent covariates and 
covariates with time-varying effects is called "dynamic prediction"15,16. 
To illustrate the clinical applicability of dynamic prediction based on the cRMST, we 
utilized a dataset from a well-known clinical study conducted at Mayo Clinic on the 
treatment of liver disease9. A dynamic prediction model (i.e., dynamic RMST model) was 
developed by landmarking15,17,18 to explore the dynamic effects of prognostic factors on 
survival time. Specific patient examples were used to illustrate how the predicted cRMST 
changed at different prediction times during follow-up. 
2.Methods 
2.1. Data sources 
This example comes from the PBC data collected by the Mayo Clinic from January 
1974 to May 1984. Follow-up was extended to April 30, 1988. A total of 312 patients 
participated in the study, of whom 158 (50.6%) were randomly assigned to receive 
D-penicillamine and 154 to receive a placebo. Patients had on average 6.23 visits, resulting 
in a total of 1945 observations. The outcome of this analysis was overall survival, which 
was calculated in years from the time of referral to death. 
There were nine baseline and time-dependent covariates that were included in the 
dynamic RMST model. Predictors measured at baseline were the drug (D-penicillamine, 
placebo), sex (female, male) and age (years). The time-dependent covariates were the 
serum bilirubin value (mg/dl), edema (yes, no), serum albumin value (g/dl), prothrombin 
time (seconds), histologic stage of disease (I/II, III, IV) and serum glutamic oxaloacetic 
transaminase (SGOT) level (U/ml). 
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2.2. Statistical analysis 
To obtain the dynamic prediction of the 5-year (w=5) cRMST, a set of landmark time 
points ( ls ) were chosen from the prediction times: in the current model, ( 0,1,...,25)ls l =  
were selected every 0.2 years from the start of follow-up. For each landmark time point ls , 
the corresponding landmark dataset lR  was constructed by selecting all patients still alive 
and undergoing follow-up at ls . Then, ˆ ( , )i lm s w , the estimator of the cRMST 
corresponding to each individual i (i=1,2,…, ln ) in lR , could be calculated (see 
Supplementary File S1) and used as a dependent variable for a generalized linear model 
(GLM): ˆ ( , | ( )) ( )Tl l l l lm s w Z s a Z s b= + . The intercept la  and coefficients 
1 2 9( , ,..., )l l l lb b b b=  are the parameters to be estimated, and 
1 2 9( ) ( ( ), ( ),..., ( ))l l l lZ s Z s Z s Z s=  are the values of the covariates at ls . All these models 
were then combined into a dynamic RMST model: ˆ ( , | ( )) ( ) ( )Tm s w Z s s Z sα β= + , where 
2
0 1 2( )s s sα α α α= + +  describes how the intercept changes over s and 1 2 9( , ,..., )β β β β=  
are the regression coefficients. The predictions of 5-year life expectancy are possible for 
any prediction time 0 25[ , ]s s s∈ . 
To test for time-varying covariate effects, interactions between covariates and s were 
then included in the dynamic RMST model: ˆ ( , ) ( ) ( ) ( )Tm s w s Z s sα β= + . The parameter 
function 1 2 9( ) ( ( ), ( ),..., ( ))s s s sβ β β β=  is a vector of functions that describes changes in 
the covariates’ effects, and 20 1 1( )j j j js s sβ β β β= + +  calculates the difference in cRMST 
resulting from a one-unit increase in the jth ( 1,2,...,9)j =  covariates at s (i.e., md(s,w)). 
Initially, all interactions were included in the model, after which the quadratic time 
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interactions were tested and removed if they had no significant effect. The covariates with 
nonsignificant quadratic time interactions were then tested for linear time interactions. 
Similarly, only the significant interactions were retained. For numeric stability, the 
prediction time was standardized using 0/ ( )Ls s s s= − . In addition, a "static" RMST 
regression model19 with 10τ =  years was established for comparison with the dynamic 
RMST model in application. 
The predictive performances of different models were evaluated by Harrell’s C-index20 
and the prediction error21. The C-index measures the probability of concordance between 
the predicted order and the observed order, while the prediction error is the difference 
between the predicted value and the observed value. A Monte-Carlo cross-validation was 
used to avoid overoptimism22. The data were divided into a training set (a 70% random 
sample) and a test set (the remaining 30%). Then, the dynamic RMST model was fitted to 
the training set and used to predict ( ,5)lm s  for these patients who were still at risk at ls  
in the test set. Performance measures (Harrell’s C-index and prediction error) were 
calculated separately for each ls . The above steps were repeated 200 times to obtain 
average C-index and prediction error values. 
All statistical tests were performed at a two-sided significance level of 0.05, and all 
analyses were performed using R software (version 3.6.1). The data underlying this article 
are open source and available in the R package 'JM'. Supplementary File S2 details the R 
code used to perform the process. 
3. Results 
The number of patients used for this analysis was 312, with a median follow-up of 6.30 
years (range: 0.11~14.31 years). During the follow-up period, 140 individuals (55.1%) died. 
The overall 5-year survival rate was 71.2% (95% CI: 66.3%-76.5%) and 10-year survival 
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rate was 47.9% (95% CI: 41.3%-55.4%). 
3.1. Effects of prognostic factors 
Table 1 shows the regression coefficients together with the standard error of the 
covariates included in the dynamic RMST model, and Fig. 3 shows the dynamic 
coefficients (i.e., difference in 5-year cRMST md(s,5) curves (w=5) with 95% confidence 
intervals). For reference, Table 2 describes the results of the RMST model. 
Drug was not statistically significant in the RMST model (Z=-0.554, P=0.579) in that 
only the patients’ referral or baseline (s=0) values for risk factors were used (Table 2). In 
contrast, in the dynamic RSMT model, patients treated with D-penicillamine had a lower 
5-year life expectancy than those taking the placebo. The dynamic coefficient of this 
covariate can be calculated by the following formula (Table 1): 
1 10 11( ) ( / 5) 0.004 0.272 ( / 5), [0,5]j s s s sβ β β= = + × = − − × ∈ , 
that is, the md(s,5) between the D-penicillamine group ( 1( ) 1Z s = ) and the placebo group 
( 1( ) 0Z s = ). The change in md(s,5) over time based on the drug is depicted in Fig. 3A. It 
can be seen that there was no significant difference (95% CI of md(0,5) contains 0) in 
5-year life expectancy between patients treated with different drugs when s=0, but the 
adverse effects of D-penicillamine increased with increasing prediction time s (the upper 
limit of the 95% CI was less than 0). This may be due to the serious side effects of 
D-penicillamine, resulting in an increased incidence of adverse events and an increased risk 
of death23. 
In addition, serum bilirubin was an important prognostic factor in PBC patients, and 
high serum bilirubin levels negatively affected the life expectancy of patients (Fig. 3B). 
Female patients had a longer life expectancy than male patients (Fig. 3C), which may be 
due to the relatively larger proportion of older patients (more than 60 years) among males 
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(42.9%) than females (15.2%). The occurrence of edema decreased the 5-year life 
expectancy, but the effect decreased with increasing prediction time s (Fig. 3D). High 
albumin levels appeared to have a protective effect with regard to the 5-year life expectancy, 
with the md(s,5) increasing from the start of follow-up (Fig. 3E). The prothrombin time 
also demonstrated a significant time-varying effect on the 5-year cRMST, with the md(s,5) 
decreasing from the start of follow-up but increasing 3 years after the time of referral (Fig. 
3F). As expected, advanced histologic stage (III and IV) were associated with a reduced 
5-year life expectancy compared with early stage (I/II). However, the md(s,5) between 
these groups decreased with increasing prediction time (Fig. 3G1-2). In contrast, the RMST 
model cannot reflect the time-varying effects of these covariates. Furthermore, age and 
SGOT level demonstrated time-constant effects on the 5-year cRMST in the dynamic 
RMST model, although the SGOT level was not statistically significant in the RMST model 
(Z=-1.826, P=0.068). 
3.2. Individual dynamic prediction 
In addition to exploring the dynamic effects of covariates on the 5-year cRMST, 
another important role of the dynamic RMST model is to provide individual dynamic 
predictions for patients. Three patients were selected from the dataset analyzed herein (see 
Table 3 for details). Fig. 4 (the solid lines) shows the 5-year cRMSTs of these patients at 
different prediction times, as derived from the dynamic RMST model. Patient A visited the 
clinic at the time of referral (s=0), that is, no time-dependent covariates were generated. 
The 5-year life expectancy of this patient remained basically unchanged (m(0,5)=2.66, 
m(5,5)=2.93), indicating that her condition was stable (Fig. 4A). Patient B visited the clinic 
two times (s=0 and s=0.665). In the time between 0 and 0.665 years, the observed values of 
some variables changed (i.e., time-dependent covariates were generated), which reduced 
the 5-year life expectancy of this patient (Fig. 4B). Patient C made annual visits to the 
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Mayo Clinic after her initial referral until her death. She had a total of 6 visits, and the 
observed values of the time-dependent covariates were different at each visit, which had an 
impact on the patient’s survival (Fig. 4C). 
The (s+5)-year RMSTs calculated by the RMST model are also shown in Fig. 4 
(dashed lines) (e.g., the horizontal axis s=0 corresponds to the 5-year RMST from the start 
of follow-up, and s=5 corresponds to the 10-year RMST from the start of follow-up). Since 
only the information at the start of follow-up (s=0) was considered, the trend in the changes 
in the RMST remains the same under different situations and does not reflect the change in 
life expectancy over prediction time. 
3.3. Model assessment 
The model assessment measures (Harrell’s C-index and prediction error) were obtained 
by the 5-year (w=5) cRMST in the dynamic RMST model from each landmark time point 
ls  (solid lines in Fig. 5). Meanwhile, the predictive performances of these corresponding 
RMST models ( ls wτ = + ) were also evaluated (dashed lines in Fig. 5). Compared with the 
RMST models, the advantages of the dynamic RMST model (a higher C-index and a lower 
prediction error) are more obvious with increasing prediction time s. 
4. Discussion 
Survival prediction is an indispensable integral part of current clinical practice; it can 
help determine optimal treatment strategies for individual patients and avoid overtreatment 
and the associated waste of medical resources. Compared with the survival rate, hazard rate 
and so on, the RMST is directly based on the concept of time, reflecting the life expectancy 
of patients up to the specified time, and therefore is a more appropriate evaluation 
measure24. In addition, the difference in the RMSTs measures the impact of different 
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treatments on survival and can be a practical and useful alternative to the HR7,25. 
However, the RMST only calculates the mean survival time of patients within a period 
of time after the start of follow-up (s = 0) and may not accurately portray the change in a 
patient’s life expectancy over time. Taking the perspective of a patient who has already 
survived a number of years, the cRMST, which is the measure proposed in this article that 
is based on the RMST, provides more relevant information by adjusting the life expectancy 
for the time the patient has already survived. In a sense, cRMST can also be understood as 
the restricted mean residual life26. 
Generally, after considering the concept of condition, the estimated value of measures 
(such as conditional survival and cRMST) will increase as the number of years survived 
increases. This relationship is usually even more obvious in patients with advanced-stage 
disease27,28. For example, in this dataset, the 5-year cRMST of patients with histologic stage 
IV disease was 3.44 years at the time of referral (i.e. m(0,5)=3.44). If the patient was still 
alive at 3 or even 5 years after referral, the 5-year cRMST would change to 3.93 
(m(3,5)=3.93) years and 4.07 (m(5,5)=4.07) years. This means an approximately 0.63-year 
increase in the 5-year life expectancy of patients who have been followed up for 5 years 
compared with those who have just been referred. This relationship actually reflects a 
natural selection effect29: due to the existence of individual differences in prognosis, 
patients with a high risk of death are very likely to experience their endpoint events in the 
initial years after the start of follow-up. Over time, as these patients expire, the surviving 
population becomes "healthier" and has a longer life expectancy. The concept of the 
cRMST is a way to quantify this phenomenon and make it easier for clinicians and patients 
to comprehend. Therefore, for patients who have been alive for a period of time, the 
cRMST provides valuable and relevant information on how their life expectancy develops 
over time. This knowledge can help motivate a patient to continue treatment, improve 
compliance, and ultimately improve survival. 
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In this paper, based on the cRMST, a dynamic RMST model was established by 
incorporating time-dependent covariates and allowing for time-varying effects, enabling the 
updating of the 5-year cRMST for PBC patients at any prediction time 0 25[ , ]s s s∈ . The 
continuous prediction of the cRMST during follow-up allows for the optimization of 
evidence-based decision-making and may improve the personalization of the treatment 
options for patients with progressive disease. In addition, compared with the RMST models 
that only use the patients’ baseline (s=0) risk factors, the dynamic RMST model has better 
predictive performance, as assessed by the C-index and prediction error. 
However, we must pay attention to several points when applying the dynamic RMST 
model. First, the time window w used depends on the severity of the disease. For severe 
diseases, w=1 or w=2 years is relevant, while for milder diseases with longer follow-up 
times, such as cirrhosis, w=5 or even w=10 years is reasonable. Second, the selection of 
landmark time points ls , which implicitly defines the weighting of the prediction time, is 
independent of the actual event time. The simplest approach is taking these points 
equidistantly in the selected interval ( 0 25[ , ]s s s∈ ). A number of time points between 20 and 
100 will be sufficient17. Finally, the functional form, such as the quadratic functions used in 
this study, of ( )sα  (how to interpret changes over s) and ( )sβ  (time-varying covariate 
effect) should be prespecified in practice. 
In summary, predicting patient survival is a complex decision-making process 
involving the patient's own factors, the disease itself, treatment programs, living 
environment and other factors. Although prediction models can help clinicians improve the 
accuracy of prediction, the prediction results cannot be blindly accepted. As Lau30 said, 
"every patient is unique, one can only observe and not determine the final journey". 




1. Trinquart L, Jacot J, Conner SC, Porcher R. Comparison of Treatment Effects 
Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in 
Oncology Randomized Controlled Trials. J Clin Oncol 2016;34:1813-9. 
2. Alexander BM, Schoenfeld JD, Trippa L. Hazards of Hazard Ratios - Deviations from 
Model Assumptions in Immunotherapy. N Engl J Med 2018;378:1158-9. 
3. Uno H, Claggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the 
between-group difference in survival analysis. J Clin Oncol 2014;32:2380-5. 
4. Uno H, Wittes J, Fu H, et al. Alternatives to hazard ratios for comparing the efficacy or 
safety of therapies in noninferiority studies. Ann Intern Med 2015;163:127-34. 
5. Li L, Yang Z, Hou Y, Chen Z. Moving beyond the Cox proportional hazards model in 
survival data analysis: a cervical cancer study. BMJ Open 2020;10:e033965. 
6. Royston P, Parmar MKB. The use of restricted mean survival time to estimate the 
treatment effect in randomized clinical trials when the proportional hazards assumption 
is in doubt. Stat Med 2011;30:2409-21. 
7. Dehbi HM, Royston P, Hackshaw A. Life expectancy difference and life expectancy 
ratio: two measures of treatment effects in randomised trials with non-proportional 
hazards. BMJ 2017;357:j2250. 
8. Hasegawa T, Misawa S, Nakagawa S, et al. Restricted mean survival time as a 
summary measure of time-to-event outcome. Pharm Stat 2020;19:436-53. 
9. Murtaugh PA, Dickson ER, Van Dam GM, et al. Primary biliary cirrhosis: Prediction of 
short-term survival based on repeated patient visits. Hepatology 1994;20:126-34. 
10. Royston P, Parmar MKB. Restricted mean survival time: an alternative to the hazard 
ratio for the design and analysis of randomized trials with a time-to-event outcome. 
BMC Med Res Methodol 2013;13:152. 
11. Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without 
Computer Methods and Programs in Biomedicine. 2021, 207: 106155
14 
 
bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall 
survival results of a phase 3 randomised trial. Lancet Oncol 2015;16:928-36. 
12. Thomas L, Reyes EM. Tutorial: survival estimation for cox regression models with 
time-varying coefficients using SAS and R. J Stat Softw 2014;61:1-23. 
13. Baulies S, Belin L, Mallon P, et al. Time-varying effect and long-term survival analysis 
in breast cancer patients treated with neoadjuvant chemotherapy. Br J Cancer 
2015;113:30-6. 
14. Chang C, Chiang AJ, Wang HC, Chen WA, Chen J. Evaluation of the time-varying 
effect of prognostic factors on survival in ovarian cancer. Ann Surg Oncol 
2015;22:3976-80. 
15. Van Houwelingen HC. Dynamic Prediction by Landmarking in Event History Analysis. 
Scand J Stat 2007;34:70-85. 
16. Fontein DBY, Klinten Grand M, Nortier JWR, et al. Dynamic prediction in breast 
cancer: proving feasibility in clinical practice using the TEAM trial. Ann Oncol 
2015;26:1254-62. 
17. Van Houwelingen HC, Putter H. Dynamic Prediction in Clinical Survival Analysis. 
Boca Raton, FL: Chapman & Hall/CRC 2012. 
18. Yang Z, Hou Y, Lyu J, Liu D, Chen Z. Dynamic prediction and prognostic analysis of 
patients with cervical cancer: a landmarking analysis approach. Ann Epidemiol 
2020;44:45-51. 
19. Andersen PK, Hansen MG, Klein JP. Regression analysis of restricted mean survival 
time based on pseudo-observations. Lifetime Data Anal 2004;10:335-50. 
20. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in 
developing models, evaluating assumptions and adequacy, and measuring and reducing 
errors. Stat Med 1996;15:361-87. 
21. Tian L, Cai T, Goetghebeur E, Wei LJ. Model evaluation based on the sampling 
Computer Methods and Programs in Biomedicine. 2021, 207: 106155
15 
 
distribution of estimated absolute prediction error. Biometrika 2007;94:297–311. 
22. Keogh RH, Seaman SR, Barrett JK, Taylor-Robinson D, Szczesniak R. Dynamic 
Prediction of Survival in Cystic Fibrosis: A Landmarking Analysis Using UK Patient 
Registry Data. Epidemiology 2019;30:29-37. 
23. Matloff DS, Alpert E, Resnick RH, Kaplan MM. A prospective trial of D-penicillamine 
in primary biliary cirrhosis. N Engl J Med 1982;306:319-26. 
24. Rutherford MJ, Andersson TM, Björkholm M, Lambert PC. Loss in life expectancy 
and gain in life years as measures of cancer impact. Cancer Epidemiol 2019;60:168-73. 
25. Stensrud MJ, Hernán MA. Why Test for Proportional Hazards? JAMA 2020; Online 
ahead of print. doi:10.1001/jama.2020.1267 
26. Mansourvar Z, Martinussen T. Estimation of average causal effect using the restricted 
mean residual lifetime as effect measure. Lifetime Data Anal 2017;23:426-38. 
27. Harshman LC, Xie W, Bjarnason GA, et al. Conditional survival of patients with 
metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a 
population-based study. Lancet Oncol 2012;13:927-35. 
28. Hieke S, Kleber M, König C, Engelhardt M, Schumacher M. Conditional Survival: A 
Useful Concept to Provide Information on How Prognosis Evolves over Time. Clin 
Cancer Res 2015;21:1530-6. 
29. Zamboni BA, Yothers G, Choi M, et al. Conditional survival and the choice of 
conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 
through C-07. J Clin Oncol 2010;28:2544-8. 
30. Lau F, Cloutier-Fisher D, Kuziemsky C, et al. A systematic review of prognostic tools 




Computer Methods and Programs in Biomedicine. 2021, 207: 106155
16 
 
Ethical approval: The data in this study is available in R package JM. No new clinical 
data was gathered or used. There is thus no need for an ethical approval. 
 
Funding: This research was supported by the National Natural Science Foundation of 
China [grant numbers 81673268, 81903411]; Natural Science Foundation of Guangdong 
Province [grant number 2018A030313849] and the Guangdong Basic and Applied Basic 
Research Foundation [grant number 2019A1515011506]. 
 








Table 1. The results of the dynamic RMST model (w=5 years) 
Variable No. ( Deaths ) Time functiona Coefficient SE P 
(Intercept)  1 7.772 0.541 <0.001
 s/5 -13.624 2.047 <0.001
 (s/5)2 11.783 2.094 <0.001
Drug (ref: placebo) 154(69)     
D-penicillamine 158(71) 1 -0.004 0.047 0.925 
 s/5 -0.272 0.094 0.004 
Sex (ref: male) 36(26)     
Female  276(114) 1 0.221 0.124 0.075 
 s/5 1.738 0.689 0.012 
 (s/5)2 -2.353 0.726 0.001 
SerBilir (per 1 mg/dl) 312(140) 1 -0.118 0.010 <0.001
 s/5 -0.147 0.051 0.004 
 (s/5)2 0.164 0.055 0.003 
Edema (ref: no) 247(96)     
Yes 65(44) 1 -0.566 0.079 <0.001
 s/5 0.311 0.150 0.038 
Albumin (per 1 gm/dl) 312(140) 1 0.278 0.074 <0.001
 s/5 0.482 0.152 0.001 
Prothrombin(per 1 second) 312(140) 1 -0.261 0.043 <0.001
 s/5 0.997 0.182 <0.001
 (s/5)2 -0.945 0.188 <0.001
Histologic (ref: Ⅰ/Ⅱ) 83(22)     
Ⅲ 120(48) 1 -0.145 0.046 0.001 
 s/5 0.280 0.104 0.007 
Ⅳ 109(70) 1 -0.567 0.060 <0.001
 s/5 0.516 0.118 <0.001
Age (per 1 year) 312(140) 1 -0.021 0.002 <0.001
SGOT (per 10 U/ml) 312(140) 1 -0.011 0.002 <0.001
Abbreviations: RMST: restricted mean survival time; No: number; SE: standard error; 
SGOT: serum glutamic oxaloacetic transaminase. 
a: The effects for covariates are calculated by the following formula:  
2
0 1 2( ) ( / 5) ( / 5)j j j js s sβ β β β= + + , 
  and the intercept for this model is calculated as 20 1 2( ) ( / 5) ( / 5)s s sα α α α= + + . 
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Table 2. The results of the RMST model ( 10τ =  years) 
Variable Coefficient 95% CI Z P 
(Intercept) 13.888 (8.625, 19.151) 5.172 <0.001 
Drug (ref: placebo)     
D-penicillamine -0.153 (-0.693, 0.387) -0.554 0.579 
Sex (ref: male)     
  Female 1.041 (0.014, 2.068) 1.987 0.047 
SerBilir (per 1 mg/dl) -0.244 (-0.312, -0.175) -6.977 <0.001 
Edema (ref: no)     
Yes -0.659 (-1.443, 0.126) -1.646 0.100 
Albumin (per 1 gm/dl) 1.432 (0.685, 2.179) 3.758 <0.001 
Prothrombin (per 1 second) -0.707 (-1.057, -0.356) -3.947 <0.001 
Histologic (ref: Ⅰ/Ⅱ)     
Ⅲ -0.761 (-1.354, -0.168) -2.513 0.012 
Ⅳ -1.409 (-2.141, -0.677) -3.771 <0.001 
Age (per 1 year) -0.051 (-0.078, -0.023) -3.610 <0.001 
SGOT (per 10 U/ml) -0.056 (-0.116, 0.004) -1.826 0.068 
Abbreviations: RMST: restricted mean survival time; CI: confidence interval; SGOT: 
serum glutamic oxaloacetic transaminase. 
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Table 3. The definition of example patients 
Patient 
Variables 
Timea Drug SerBilir Sex Edema Albumin Prothrombin Histologic Age SGOT
A 0.000 D-penicil 1.4 female Yes 3.13 12.2 Ⅳ 77 86.8
B 0.000 D-penicil 2.4 male No 3.83 10.3 Ⅲ 35 127.0
B 0.665 D-penicil 3.0 male No 3.75 10.5 Ⅳ 35 161.0
C 0.000 placebo 5.2 female No 3.68 9.9 Ⅲ 52 165.9
C 0.545 placebo 6.6 female No 2.87 11.4 Ⅲ 52 196.9
C 1.035 placebo 5.8 female No 2.94 10.4 Ⅳ 52 210.8
C 2.029 placebo 6.0 female Yes 2.60 11.6 Ⅳ 52 207.7
C 2.984 placebo 9.0 female Yes 2.54 10.4 Ⅳ 52 241.0
C 3.926 placebo 16.2 female Yes 1.81 12.5 Ⅳ 52 241.0
Abbreviations: SGOT: serum glutamic oxaloacetic transaminase. 
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